The differential effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with respect to foot ulcer and limb amputation in those with diabetes

Wound Repair and Regeneration

Volumn 18, Issue 5, 2010, Pages 445-451

  Margolis, David J ^a   Hoffstad, Ole ^a   Thom, Stephen ^a   Bilker, Warren ^a   Maldonado, Arturo R ^b   Cohen, Robert M ^c   Aronow, Bruce J ^b   Crombleholme, Timothy ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTERY DISEASE; ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EXPOSURE; FEMALE; FOOT ULCER; HUMAN; LEG AMPUTATION; LIMB AMPUTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; UNITED KINGDOM; WOUND HEALING;

ADULT; AGED; AMPUTATION; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; ENGLAND; FEMALE; FOLLOW-UP STUDIES; FOOT ULCER; HUMANS; LEG; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WALES;

EID: 77956640219     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/j.1524-475X.2010.00624.x     Document Type: Article

References (31)

1. Kalaitzidis R, Bakris G. Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy? Postgrad Med 2009 121: 77 88.
2. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008 372: 547 553.
3. Ram CV. Angiotensin receptor blockers: current status and future prospects. Am J Med 2008 121: 656 663.
4. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009 361: 40 51.
5. Schmieder RE. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hyperten 2005 18 (Part 1): 720 730.
6. McDonald MA, Simpson SH, Ezekowitz JA, Gyenes G, Tsuyuki RT. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 2005 331: 873 876.
7. Bohm M. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now? Am J Cardiol 2007 100: 38J 44J.
8. Khakoo AY, Sidman RL, Pasqualini R, Arap W. Does the renin-angiotensin system participate in regualtion of human vasculogenesis and angiogenesis? Cancer Res 2008 68: 9112 9115.
9. Wrobel JS, Mayfield JA, Reiber GE. Geographic variation of lower-extremity major amputation in individuals with and without diabetes in the Medicare population. Diabetes Care 2001 24: 860 864.
10. Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, Terney EF, Rios-Burrows N, Mokdad AH, Ford ES, Imperatore G, Narayan KM. The evolving diabetes burden in the united states. Ann Intern Med 2004 140: 945 950.
11. Margolis DJ, Hofstad O, Feldman HI. Association between renal failure and foot ulcer or lower-extremity amputation in patients with diabetes. Diabetes Care 2008 31: 1331 1336.
12. Lewis JD, Shinnar R, Bilker W, Wang X, Strom BL. Validation studies of the health improvement network for pharmacoepidemiology studies. Pharmacoepidemiol Drug Safety 2007 16: 393 401.
13. Onuigbo MA, Onuigbo MAC. Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET - a call for more circumspection. QJM 2009 102: 155 167.
14. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009 373: 2125 2135.
15. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005 366: 2026 2033.
16. Erkens JA, Klungel OH, Stolk RP, Spoelstra JA, Grobbee DE, Leufkens HG. Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients. Pharmacoepidemiol Drug Safety 2004 13: 139 146.
17. ONTARGET investigators. Telmisartan, Ramipril or both in patients at high risk for vascular events. N Engl J Med 2008 358: 1547 1559.
18. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993 91: 2268 2274.
19. Page EL, Robitaille GA, Pouyssegur J, Richard DE. Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J Biol Chem 2002 277: 48403 48409.
20. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem 2000 275: 26765 26771.
21. Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y, Masaki H, Uchiyama Y, Koyama Y, Nose A, Iba O, Tateishi E, Ogata N, Jyo N, Higashiyama S, Iwasaka T. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res 2001 88: 22 9.
22. Huang HR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway in angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003 14: 1738 1747.
23. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998 83: 1182 1191.
24. Ritter O, Schuh K, Brede M, Rothlein N, Burkard N, Hein L, Neyses L. AT2 receptor activation regulates myocardial eNOS expression via the calcineurin-NF-AT pathway. FASEB J 2003 17: 283 285.
25. Savoia C, Ebrahimian T, He Y, Gratton JP, Schiffrin EL, Touyz RM. Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. J Hypertension 2006 24: 2417 2422.
26. Goldstein LJ, Gallagher KA, Bauer SM, Bauer RJ, Baireddy V, Liu ZJ, Buerk DG, Thom SR, Velazquez OC. Endothelial progenitor cell release into circulation is triggered by hyperoxia-induced increases in bone marrow nitric oxide. Stem Cells 2006 24: 2309 2318.
27. Thom SR, Bhopale VM, Velazquez OC, Goldstein LJ, Thom LH, Buerk DG. Stem cell mobilization by hyperbaric oxygen. Am J Physiol - Heart Circulatory Physiol 2006 290: H1378 86.
28. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. [erratum appears in Circulation 2006 Nov 7;114(19):e576]. Circulation 2006 114: 838 854.
29. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. [see comment]. N Engl J Med 2005 353: 999 1007.
30. Perkins BA, Aiello LP, Krolewski AS. Diabetes complications and the renin-angiotensin system. N Engl J Med 2009 361: 83 5.
31. Jerums G, Panagiotopoulos S, Premaratne E, Power DA. Lowering of proteinuria in response to antihypertensive therapy predicts improved renal function in late but not in early diabetic nephropathy: a pooled analysis. Am J Nephrol 2008 28: 614 627.